Newsroom

Analysis conducted on a hierarchical endpoint comprised of mortality, HF hospitalization, and health status shows that patients treated with phrenic nerve stimulation may be nearly five times as likely to experience a clinical benefit compared to those in the control group.

Expanded insurance coverage now available in Utah, Idaho and Nevada

ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).

ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study.